The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The Anemia And Other Blood Disorder Drugs Market By The End Of 2030?
The anemia and other blood disorder drugs market size has shown robust expansion in recent years. It is projected to expand from $12.46 billion in 2025 to $13.14 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.5%. This historical growth can be linked to several key factors, including the high incidence of iron deficiency anemia, the prevalence of chronic kidney disease, reliance on blood transfusions, long-standing use of esAs, and established hematology treatment protocols.
The anemia and other blood disorder drugs market is anticipated to show significant expansion in the coming years. Its value is projected to reach $16.88 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.5%. This forecasted growth is primarily fueled by increased adoption of gene therapy, an expanding aging population, heightened awareness of blood disorders, the establishment of more specialty hematology clinics, and better diagnostic rates. Noteworthy trends during this period encompass a rise in the prevalence of chronic blood disorders, greater utilization of injectable therapies, the broader application of gene therapy for rare anemias, an intensifying focus on personalized hematology treatments, and improved access to vital blood disorder medications.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp
What Drivers Are Shaping The Future Growth Of The Anemia And Other Blood Disorder Drugs Market?
The increasing demand for personalized medicine is projected to drive the expansion of the anemia and other blood disorder drugs market in the future. Personalized medicine represents a healthcare strategy that utilizes an individual’s genetic blueprint to direct choices in prevention, diagnosis, and treatment. The escalating need for personalized medicine stems from its capacity to offer more potent and precisely targeted therapies, which in turn enhance patient outcomes and promote enduring health. The anemia and other blood disorder drugs market facilitates personalized care by allowing for customized treatment regimens that target specific genetic or molecular attributes of blood conditions. For example, in May 2024, data from the American Psychiatric Association, a US-based non-profit organization, showed that 43% of adults reported feeling more anxious than in the prior year, an increase from 37% in 2023 and 32% in 2022. Thus, the growing inclination towards personalized medicine is fostering the development of the anemia and other blood disorder drugs market.
Which Segment Classifications Shape The Anemia And Other Blood Disorder Drugs Market?
The anemia and other blood disorder drugs market covered in this report is segmented –
1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia
2) By Route of Administration: Oral, Injectable
3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
Subsegments:
1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods
2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion
3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs
4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)
How Are Trends Impacting The Anemia And Other Blood Disorder Drugs Market?
Major companies in the anemia and other blood disorder drugs market are concentrating on introducing innovative medications to enhance therapeutic outcomes, expand treatment possibilities, and reinforce their competitive stance. Novel medications are defined as pioneering pharmaceutical treatments that offer new modes of action, improved effectiveness, or enhanced safety profiles compared to existing therapies, thereby addressing unfulfilled medical needs in conditions such as anemia and myelodysplastic syndromes. For instance, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical company, obtained FDA approval for Reblozyl as the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes. This marks the first therapy to demonstrate superiority over an erythropoiesis-stimulating agent in this setting, corroborated by Phase 3 COMMANDS trial data showing that nearly twice as many Reblozyl-treated patients achieved at least 12 weeks of transfusion independence with concurrent hemoglobin improvement compared to those receiving Epoetin alfa.
Which Companies Are Expanding Their Footprint In The Anemia And Other Blood Disorder Drugs Market?
Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.
Read the full anemia and other blood disorder drugs market report here:
Which Geographic Regions Are Influencing Demand In The Anemia And Other Blood Disorder Drugs Market?
North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Anemia And Other Blood Disorder Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=2465&type=smp
Browse Through More Reports Similar to the Global Anemia And Other Blood Disorder Drugs Market 2026, By The Business Research Company
Anemia And Other Blood Disorder Drugs Market Report 2026
Chemotherapy Induced Anemia Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Hematology Drug Market Report 2026
https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model